Longevity & AgingOligomerix Completes Phase 1a Trial of Oral Tau-Targeting Alzheimer's Pill
Oligomerix has completed a Phase 1a clinical trial for OLX-07010, an experimental pill targeting tau proteins linked to Alzheimer's disease. Unlike most Alzheimer's treatments requiring clinic infusions, this is an oral therapy designed to prevent tau proteins from clumping together — a process that destroys neuron communication and drives cognitive decline. The trial enrolled 76 healthy volunteers receiving doses from 25mg to 200mg. Results showed a favorable safety profile and drug exposure levels matching researchers' targets. While this early stage only tests safety, not effectiveness, it marks a significant step forward. The drug now has a foundation for trials in actual Alzheimer's patients. For anyone concerned about cognitive aging, this represents a promising new angle in dementia prevention research.
